COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,845 Articles (22,553 medRxiv, 8,292 bioRxiv)

Most recent first Previous |  Page 1025: Articles 10241-10250  | Next

COVID-19 vaccine hesitancy in diverse groups in the UK - is the driver economic or cultural in student populations?
Drobniewski, F., Kusuma, D., Broda, A., Castro-Sanchez, E., Ahmad, R.
10.1101/2021.12.14.21267773 — Posted: 2021-12-15
COVID-19 vaccination and Guillain-Barre syndrome: analyses using the National Immunoglobulin Database
Keh, R. Y. S., Scanlon, S., Datta-Nemdharry, P., Donegan, K., Cavanagh, S., Foster, M., Skelland, D., Palmer, J., Machado, P., Carr, A., Lunn, M., BPNS/ABN COVID-19 Vaccine GBS Study Group
10.1101/2021.12.14.21267418 — Posted: 2021-12-15
Acute COVID-19 severity and 16-month mental morbidity trajectories in patient populations of six nations
Magnusdottir, I., Lovik, A., Unnarsdottir, A. B., McCartney, D. L., Ask, H., Koiv, K., Nordahl Christoffersen, L. A., Johnson, S. U., McIntosh, A. M., Kahler, A. K., Campbell, A., Hauksdottir, A., Fawns-Ritchie, C., Erikstrup, C., Helenius, D., Altschul, D., Thordardottir, E. B., Eythorsson, E., Frans, E. M., Tomasson, G., Jonsdottir, H. L., Runarsdottir, H., Hjalgrim, H., Hardardottir, H., Gonzalez-Hijon, J., Banasik, K., Dinh, K. M., Lu, L., Milani, L., Trogstad, L., Didriksen, M., Ebrahimi, O. V., Sullivan, P. F., Magnus, P. M., Shen, Q., Nesvag, R., Magi, R., Palsson, R., Rye Ostrowski, S., Werge, T., Hoffart, A., Porteous, D. J., Fang, F., Jakobsdottir, J., Lehto, K., Andreassen, O. A., Pedersen, O. B. V., Aspelund, T., Valdimarsdottir, U. A.
10.1101/2021.12.13.21267368 — Posted: 2021-12-15
Antibody-mediated Immunogenicity against SARS-CoV-2 following priming, boosting and hybrid immunity: insights from 11 months of follow-up of a healthcare worker cohort in Israel, December 2020-October 2021
Edelstein, M., Beiruti, K., Ben Amram, H., Bar Zeev, N., Sussan, C., Assulin, H., Strauss, D., Bathish, Y., Zarka, S., Abu Jabal, K.
10.1101/2021.12.15.21267793 — Posted: 2021-12-15
Simulation of the omicron variant of SARS-CoV-2 shows broad antibody escape, weakened ACE2 binding, and modest increase in furin binding
Jawaid, M.- Z., Baidya, A., Mahboubi-Ardakani, R., Davis, R. L., Cox, D. L.
10.1101/2021.12.14.472704 — Posted: 2021-12-15
SARS-CoV-2 Spike protein activates TMEM16F-mediated platelet pro-coagulant activity
Giacca, M., Cappelletto, A., Allan, H. E., Crescente, M., Schneider, E., Bussani, R., Ali, H., Secco, I., Vodret, S., Simeone, R., Mascaretti, L., Zacchigna, S., Warner, T. D.
10.1101/2021.12.14.472668 — Posted: 2021-12-15
Compared with SARS-CoV2 wild type's spike protein, the SARS-CoV2 omicron's receptor binding motif has adopted a more SARS-CoV1 and/or bat/civet-like structure.
Glocker, M. O., Opuni, K. F. M., Thiesen, H.-J.
10.1101/2021.12.14.472585 — Posted: 2021-12-15
Development and Characterization of Recombinant Vesicular Stomatitis Virus (rVSV)-based Bivalent Vaccine Against COVID-19 Delta Variant and Influenza Virus
Ao, Z., Jing Ouyang, M., Olukitibi, T. A., Warner, B., Vendramelli, R., Truong, T., Zhang, M., Kung, S., Fowke, K. R., Kobasa, D., Yao, X.
10.1101/2021.12.14.472657 — Posted: 2021-12-15
Computational analysis of the effect of SARS-CoV-2 variant Omicron Spike protein mutations on dynamics, ACE2 binding and propensity for immune escape
Teruel, N., Crown, M., Bashton, M., Najmanovich, R.
10.1101/2021.12.14.472622 — Posted: 2021-12-15
Considerable escape of SARS-CoV-2 variant Omicron to antibody neutralization
Planas, D., Saunders, N., Maes, P., Benhassine, F. G., Planchais, C., Porrot, F., Staropoli, I., Lemoine, F., Pere, H., Veyer, D., Puech, J., Rodary, J., Bolland, W. H., Buchrieser, J., Baele, G., Dellicour, S., Raymenants, J., Gorissen, S., Geenen, C., Vanmechelen, B., Wawina, T., Marti, J., Cuypers, L., Seve, A., Hocqueloux, L., Prazuck, T., Loriere, E. S., REY, F., Bruel, T., Mouquet, H., Andre, E., Schwartz, O.
10.1101/2021.12.14.472630 — Posted: 2021-12-15

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).